MRVL Stock Recent News

Zacks.com users have recently been watching Marvell (MRVL) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

I am upgrading to a “Strong Buy” rating on Marvell Technology, driven by their custom silicon products supporting Amazon's Trainium AI chips and Alphabet's AI developments. Amazon's Trainium2, supported by Marvell, offers significant cost and performance advantages, potentially competing with Nvidia's AI chips and driving Marvell's revenue growth. Marvell anticipates $1.5 billion in AI-related revenue for FY25 and $2.5 billion for FY26, with strong growth in their custom silicon business.

CNBC's Jim Cramer delivers his daily Mad Dash.

Extends PAM4 Connectivity Leadership to Scale Next Generation AI Server Compute Fabrics SANTA CLARA, Calif. , Oct. 15, 2024 /PRNewswire/ -- OCP Global Summit – Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, demonstrates its industry-leading 3nm PCIe Gen 7 connectivity at the OCP Global Summit, October 15-17, at the San Jose Convention Center.

Marvell Technologies is working with big tech to price custom ASIC solutions. This sets up the company well if the tech companies decide to scale up their new AI projects.

Data Center Portfolio Powers the Next Generation of AI and Cloud SANTA CLARA, Calif. , Oct. 14, 2024 /PRNewswire/ -- 2024 OCP Global Summit – Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, will highlight its latest advancements in accelerated infrastructure at the 2024 OCP Global Summit, October 15-17, in San Jose, California.

Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs.

While MRVL's exposure to China and elevated valuation are legitimate concerns, its promising product pipeline and efficient execution make the stock worth holding on to.

Marvell's data center revenue soared 92% year-over-year in Q2, now making up 69% of total revenue. Marvell capitalizes on AI demand with custom silicon solutions, targeting a $421 billion AI market by 2033. The giant introduced the industry's first 1.6 Tbps DSP and 800G DSPs, enhancing data transfer speeds for AI workloads.